Protocol Ledger

NCT06758401 · Phase III · RECRUITING

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Interventional Phase III clinical trial protocol NCT06758401 sponsored by Pfizer in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-07-23 Enrollment: 714 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06758401
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)714 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06758401
Protocol FieldVerified Registry Value
NCT IdentifierNCT06758401
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment714 participants (ESTIMATED)
Registered Start Date2025-07-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06758401
Hospital Research SiteLocationSite Profile
Providence Medical FoundationFullerton, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI